Use of Telemedicine to Improve Adherence to American Diabetes Association Standards in Pediatric Type 1 Diabetes
Overview
Pharmacology
Affiliations
Background: The American Diabetes Association (ADA) recommends that children with type 1 diabetes (T1D) see a multidisciplinary team and have hemoglobin A1c (A1C) levels measured every 3 months. Patients in rural areas may not follow guidelines because of limited specialty care access. We hypothesized that videoconferencing would result in equivalent A1C compared with in-person visits and increased compliance with ADA recommendations.
Materials And Methods: The Barbara Davis Center (BDC) (Aurora, CO) telemedicine program provides diabetes care to pediatric patients in Casper and Cheyenne, WY, via remote consultation with annual in-person visits. Over 27 months, 70 patients were consented, and 54 patients completed 1 year in the study.
Results: Patients were 70% male, with a mean age of 12.1 ± 4.1 years and T1D duration of 5.4 ± 4.1 years. There was no significant change between baseline and 1-year A1C levels for patients with data at both time points. Patients saw diabetes specialists an average of 2.0 ± 1.3 times per year in the year prior to starting telemedicine and 2.9 ± 1.3 times (P < 0.0001) in the year after starting telemedicine. Patients and families missed significantly less school and work time to attend appointments.
Conclusions: Our study suggests telemedicine is equivalent to in-person visits to maintain A1C, whereas families increase the number of visits in line with ADA recommendations. Patients and families miss less school and work. Decreased financial burden and increased access may improve overall diabetes care and compliance for rural patients. Further study is needed to detect long-term differences in complications screenings and the financial impact of telemedicine on pediatric diabetes care.
Rajan R, Dovbenyuk R, Kshatriya M, Yanikomeroglu S, Banfield L, Athale U Adolesc Health Med Ther. 2025; 15:109-117.
PMID: 40017672 PMC: 11865916. DOI: 10.2147/AHMT.S482859.
Esposito S, Sambati V, Fogliazza F, Street M, Principi N Front Endocrinol (Lausanne). 2025; 15:1513166.
PMID: 39758346 PMC: 11695225. DOI: 10.3389/fendo.2024.1513166.
Fogliazza F, Sambati V, Iovane B, Lazzeroni P, Street M, Esposito S J Clin Med. 2024; 13(23).
PMID: 39685817 PMC: 11642187. DOI: 10.3390/jcm13237359.
Parkinson A, Brew-Sam N, Dykgraaf S, Nolan C, Lafferty A, Schmidli R Integr Healthc J. 2024; 3(1):e000082.
PMID: 38607941 PMC: 8593267. DOI: 10.1136/ihj-2021-000082.
Hunter B, Brown-Gentry K, Santilli M, Prasla K J Manag Care Spec Pharm. 2024; 30(4):364-375.
PMID: 38555626 PMC: 10982573. DOI: 10.18553/jmcp.2024.30.4.364.